• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Edesa Biotech Inc. (Amendment)

    1/13/23 5:28:47 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EDSA alert in real time by email
    SC 13D/A 1 brhc10046676_sc13da.htm SC 13D/A

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13D
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
     

     
    EDESA BIOTECH, INC.
    (Name of Issuer)
     
    Common Shares, no par value per share
    (Title of Class of Securities)
     
    27966L108
    (CUSIP Number)
     
    Vasco Larcina
    c/o Lumira Capital Investment Management
    141 Adelaide Street West, Suite 770
    Toronto, Ontario, M5H 3L5, Canada
    (416) 213-4251
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    January 10, 2023
    (Date of Event which Requires Filing of this Statement)
     

     
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐
     
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


    CUSIP No.  27966L108
     
    Page     2      of     16       Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Lumira Capital II, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Ontario, Canada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,600,932 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,600,932 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,600,932 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    8.2% (2)(3)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     
    (1) Includes (a) 1,504,390 Common Shares and (b) 96,542 Class A Warrants, with each Class A Warrant exercisable for one Common Share at a purchase price of $4.80 per Common Share.
     
    (2) Represents the quotient obtained by dividing (a) the aggregate amount beneficially owned by the Reporting Persons in Row 11 by (b) the sum of (i) 19,353,351 Common Shares issued and outstanding as of December 14, 2022, as reported in the Issuer’s Annual Report on Form 10-K filed with the Commission on December 16, 2022, plus (ii) 96,542 Warrants issuable upon the exercise of the Warrants held by the Reporting Persons (defined below).
     
    (3) The number of Warrants beneficially owned by the Reporting Persons (defined below) are treated as converted into Common Shares only for the purpose of computing the percentage ownership of the Reporting Persons for the purpose of this Schedule 13D pursuant to Rule 13d-3 of the Exchange Act. Such percentage ownership does not give effect to the aggregate voting power of the Warrants, as the Warrants are treated as converted into Common Shares for the purpose of this Schedule 13D.
     

    CUSIP No.  27966L108
     
    Page     3      of     16       Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Lumira Capital II (International), L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Ontario, Canada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    148,038 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    148,038 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    148,038 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.8% (2)(3)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1) Includes (a) 139,110 Common Shares and (b) 8,928 Class A Warrants, with each Class A Warrant exercisable for one Common Share at a purchase price of $4.80 per Common Share.
     
    (2) Represents the quotient obtained by dividing (a) the aggregate amount beneficially owned by the Reporting Persons in Row 11 by (b) the sum of (i) 19,353,351 Common Shares issued and outstanding as of December 14, 2022, as reported in the Issuer’s Annual Report on Form 10-K filed with the Commission on December 16, 2022, plus (ii) 8,928 Warrants issuable upon the exercise of the Warrants held by the Reporting Persons (defined below).
     
    (3) The number of Warrants beneficially owned by the Reporting Persons (defined below) are treated as converted into Common Shares only for the purpose of computing the percentage ownership of the Reporting Persons for the purpose of this Schedule 13D pursuant to Rule 13d-3 of the Exchange Act. Such percentage ownership does not give effect to the aggregate voting power of the Warrants, as the Warrants are treated as converted into Common Shares for the purpose of this Schedule 13D.
     
    3

    CUSIP No.  27966L108
     
    Page     4      of     16       Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Lumira Capital GP, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Ontario, Canada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,748,970 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,748,970 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,748,970 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    9.0% (2)(3)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1) Includes (a) 1,643,500 Common Shares and (b) 105,470 Class A Warrants, with each Class A Warrant exercisable for one Common Share at a purchase price of $4.80 per Common Share.
     
    (2) Represents the quotient obtained by dividing (a) the aggregate amount beneficially owned by the Reporting Persons in Row 11 by (b) the sum of (i) 19,353,351 Common Shares issued and outstanding as of December 14, 2022, as reported in the Issuer’s Annual Report on Form 10-K filed with the Commission on December 16, 2022, plus (ii) 105,470 Warrants issuable upon the exercise of the Warrants held by the Reporting Persons (defined below).
     
    (3) The number of Warrants beneficially owned by the Reporting Persons (defined below) are treated as converted into Common Shares only for the purpose of computing the percentage ownership of the Reporting Persons for the purpose of this Schedule 13D pursuant to Rule 13d-3 of the Exchange Act. Such percentage ownership does not give effect to the aggregate voting power of the Warrants, as the Warrants are treated as converted into Common Shares for the purpose of this Schedule 13D.
     
    4

    CUSIP No.  27966L108
     
    Page     5      of     16       Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Lumira GP Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Canada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,748,970 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,748,970 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,748,970 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    9.0% (2)(3)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     

    (1) Includes (a) 1,643,500 Common Shares and (b) 105,470 Class A Warrants, with each Class A Warrant exercisable for one Common Share at a purchase price of $4.80 per Common Share.
     
    (2) Represents the quotient obtained by dividing (a) the aggregate amount beneficially owned by the Reporting Persons in Row 11 by (b) the sum of (i) 19,353,351 Common Shares issued and outstanding as of December 14, 2022, as reported in the Issuer’s Annual Report on Form 10-K filed with the Commission on December 16, 2022, plus (ii) 105,470 Warrants issuable upon the exercise of the Warrants held by the Reporting Persons (defined below).
     
    (3) The number of Warrants beneficially owned by the Reporting Persons (defined below) are treated as converted into Common Shares only for the purpose of computing the percentage ownership of the Reporting Persons for the purpose of this Schedule 13D pursuant to Rule 13d-3 of the Exchange Act. Such percentage ownership does not give effect to the aggregate voting power of the Warrants, as the Warrants are treated as converted into Common Shares for the purpose of this Schedule 13D.
     
    5

    CUSIP No.  27966L108
     
    Page     6      of     16       Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Lumira GP Holdings Co.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Nova Scotia, Canada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,748,970 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,748,970 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,748,970 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    9.0% (2)(3)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     

    (1) Includes (a) 1,643,500 Common Shares and (b) 105,470 Class A Warrants, with each Class A Warrant exercisable for one Common Share at a purchase price of $4.80 per Common Share.
     
    (2) Represents the quotient obtained by dividing (a) the aggregate amount beneficially owned by the Reporting Persons in Row 11 by (b) the sum of (i) 19,353,351 Common Shares issued and outstanding as of December 14, 2022, as reported in the Issuer’s Annual Report on Form 10-K filed with the Commission on December 16, 2022, plus (ii) 105,470 Warrants issuable upon the exercise of the Warrants held by the Reporting Persons (defined below).
     
    (3) The number of Warrants beneficially owned by the Reporting Persons (defined below) are treated as converted into Common Shares only for the purpose of computing the percentage ownership of the Reporting Persons for the purpose of this Schedule 13D pursuant to Rule 13d-3 of the Exchange Act. Such percentage ownership does not give effect to the aggregate voting power of the Warrants, as the Warrants are treated as converted into Common Shares for the purpose of this Schedule 13D.
     
    6

    CUSIP No.  27966L108
     
    Page     7      of     16       Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Lumira Capital Investment Management Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Canada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,748,970 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,748,970 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,748,970 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    9.0% (2)(3)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     

    (1) Includes (a) 1,643,500 Common Shares and (b) 105,470 Class A Warrants, with each Class A Warrant exercisable for one Common Share at a purchase price of $4.80 per Common Share.
     
    (2) Represents the quotient obtained by dividing (a) the aggregate amount beneficially owned by the Reporting Persons in Row 11 by (b) the sum of (i) 19,353,351 Common Shares issued and outstanding as of December 14, 2022, as reported in the Issuer’s Annual Report on Form 10-K filed with the Commission on December 16, 2022, plus (ii) 105,470 Warrants issuable upon the exercise of the Warrants held by the Reporting Persons (defined below).
     
    (3) The number of Warrants beneficially owned by the Reporting Persons (defined below) are treated as converted into Common Shares only for the purpose of computing the percentage ownership of the Reporting Persons for the purpose of this Schedule 13D pursuant to Rule 13d-3 of the Exchange Act. Such percentage ownership does not give effect to the aggregate voting power of the Warrants, as the Warrants are treated as converted into Common Shares for the purpose of this Schedule 13D.
     
    7

    CUSIP No.  27966L108
     
    Page     8      of     16       Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Peter van der Velden
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Canadian
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,748,970 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,748,970 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,748,970 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    9.0% (2)(3)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    (1) Includes (a) 1,643,500 Common Shares and (b) 105,470 Class A Warrants, with each Class A Warrant exercisable for one Common Share at a purchase price of $4.80 per Common Share.
     
    (2) Represents the quotient obtained by dividing (a) the aggregate amount beneficially owned by the Reporting Persons in Row 11 by (b) the sum of (i) 19,353,351 Common Shares issued and outstanding as of December 14, 2022, as reported in the Issuer’s Annual Report on Form 10-K filed with the Commission on December 16, 2022, plus (ii) 105,470 Warrants issuable upon the exercise of the Warrants held by the Reporting Persons (defined below).
     
    (3) The number of Warrants beneficially owned by the Reporting Persons (defined below) are treated as converted into Common Shares only for the purpose of computing the percentage ownership of the Reporting Persons for the purpose of this Schedule 13D pursuant to Rule 13d-3 of the Exchange Act. Such percentage ownership does not give effect to the aggregate voting power of the Warrants, as the Warrants are treated as converted into Common Shares for the purpose of this Schedule 13D.
     
    8

    CUSIP No.  27966L108
     
    Page     9      of     16       Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Benjamin Rovinski
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Canadian
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,748,970 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,748,970 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,748,970 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    9.0% (2)(3)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    (1) Includes (a) 1,643,500 Common Shares and (b) 105,470 Class A Warrants, with each Class A Warrant exercisable for one Common Share at a purchase price of $4.80 per Common Share.
     
    (2) Represents the quotient obtained by dividing (a) the aggregate amount beneficially owned by the Reporting Persons in Row 11 by (b) the sum of (i) 19,353,351 Common Shares issued and outstanding as of December 14, 2022, as reported in the Issuer’s Annual Report on Form 10-K filed with the Commission on December 16, 2022, plus (ii) 105,470 Warrants issuable upon the exercise of the Warrants held by the Reporting Persons (defined below).
     
    (3) The number of Warrants beneficially owned by the Reporting Persons (defined below) are treated as converted into Common Shares only for the purpose of computing the percentage ownership of the Reporting Persons for the purpose of this Schedule 13D pursuant to Rule 13d-3 of the Exchange Act. Such percentage ownership does not give effect to the aggregate voting power of the Warrants, as the Warrants are treated as converted into Common Shares for the purpose of this Schedule 13D.
     
    9

    CUSIP No.  27966L108
     
    Page     10      of     16       Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Daniel Hetu
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Canadian
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,748,970 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,748,970 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,748,970 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    9.0% (2)(3)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    (1) Includes (a) 1,643,500 Common Shares and (b) 105,470 Class A Warrants, with each Class A Warrant exercisable for one Common Share at a purchase price of $4.80 per Common Share.
     
    (2) Represents the quotient obtained by dividing (a) the aggregate amount beneficially owned by the Reporting Persons in Row 11 by (b) the sum of (i) 19,353,351 Common Shares issued and outstanding as of December 14, 2022, as reported in the Issuer’s Annual Report on Form 10-K filed with the Commission on December 16, 2022, plus (ii) 105,470 Warrants issuable upon the exercise of the Warrants held by the Reporting Persons (defined below).
     
    (3) The number of Warrants beneficially owned by the Reporting Persons (defined below) are treated as converted into Common Shares only for the purpose of computing the percentage ownership of the Reporting Persons for the purpose of this Schedule 13D pursuant to Rule 13d-3 of the Exchange Act. Such percentage ownership does not give effect to the aggregate voting power of the Warrants, as the Warrants are treated as converted into Common Shares for the purpose of this Schedule 13D.
     
    10

    CUSIP No.  27966L108
     
    Page     11      of     16       Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Gerald Brunk
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,748,970 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,748,970 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,748,970 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    9.0% (2)(3)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    (1) Includes (a) 1,643,500 Common Shares and (b) 105,470 Class A Warrants, with each Class A Warrant exercisable for one Common Share at a purchase price of $4.80 per Common Share.
     
    (2) Represents the quotient obtained by dividing (a) the aggregate amount beneficially owned by the Reporting Persons in Row 11 by (b) the sum of (i) 19,353,351 Common Shares issued and outstanding as of December 14, 2022, as reported in the Issuer’s Annual Report on Form 10-K filed with the Commission on December 16, 2022, plus (ii) 105,470 Warrants issuable upon the exercise of the Warrants held by the Reporting Persons (defined below).
     
    (3) The number of Warrants beneficially owned by the Reporting Persons (defined below) are treated as converted into Common Shares only for the purpose of computing the percentage ownership of the Reporting Persons for the purpose of this Schedule 13D pursuant to Rule 13d-3 of the Exchange Act. Such percentage ownership does not give effect to the aggregate voting power of the Warrants, as the Warrants are treated as converted into Common Shares for the purpose of this Schedule 13D.
     
    11

    CUSIP No.  27966L108
     
    Page     12      of     16      Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Vasco Larcina
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Canadian
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,748,970 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,748,970 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,748,970 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    9.0% (2)(3)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    (1) Includes (a) 1,643,500 Common Shares and (b) 105,470 Class A Warrants, with each Class A Warrant exercisable for one Common Share at a purchase price of $4.80 per Common Share.
     
    (2) Represents the quotient obtained by dividing (a) the aggregate amount beneficially owned by the Reporting Persons in Row 11 by (b) the sum of (i) 19,353,351 Common Shares issued and outstanding as of December 14, 2022, as reported in the Issuer’s Annual Report on Form 10-K filed with the Commission on December 16, 2022, plus (ii) 105,470 Warrants issuable upon the exercise of the Warrants held by the Reporting Persons (defined below).
     
    (3) The number of Warrants beneficially owned by the Reporting Persons (defined below) are treated as converted into Common Shares only for the purpose of computing the percentage ownership of the Reporting Persons for the purpose of this Schedule 13D pursuant to Rule 13d-3 of the Exchange Act. Such percentage ownership does not give effect to the aggregate voting power of the Warrants, as the Warrants are treated as converted into Common Shares for the purpose of this Schedule 13D.
     
    12

    This Amendment No. 3 (“Amendment No. 3”) amends and supplements the statement on Schedule 13D jointly filed by (i) Lumira Capital II, L.P., formed in Ontario, Canada (ii) Lumira Capital II (International), L.P., formed in Ontario, Canada , (iii) Lumira Capital GP, L.P., formed in Ontario, Canada, (iv) Lumira GP Inc., formed in Canada, (v) Lumira GP Holdings Co., formed in Nova Scotia, Canada (vi) Lumira Capital Investment Management Inc., formed in Ontario, Canada, (vii) Peter van der Velden, an individual and a Canadian citizen, (viii) Benjamin Rovinski, an individual and a Canadian citizen, (ix) Daniel Hetu, an individual and a Canadian citizen,  (x) Gerald Brunk, an individual and a United States citizen and (xi) Vasco Larcina, an individual and a Canadian citizen (collectively, the “Reporting Persons”) on June 17, 2019 as amended by Amendment No. 1 and No. 2 filed by the Reporting Persons on August 19, 2019 and January 16, 2020, respectively (as so amended and supplemented, the “Schedule 13D”), with respect to the common shares, no par value per share (the “Common Shares”) of Edesa Biotech, Inc., a British Columbia corporation, formerly known as “Stellar Biotechnologies, Inc.” (the “Company” or the “Issuer”). Except as expressly amended by this Amendment No. 3, the Schedule 13D remains in full force and effect.

    The purpose of this Amendment No. 3 is to report a decrease in the Reporting Persons’ beneficial ownership of Common Shares as a result of the disposition of Common Shares from January 9th to 12th, 2023, as described in this Amendment No. 3.

    Item 1.
    Security and Issuer.

    This Schedule 13D relates to the Common Shares of the Company, which has its principal executive offices at 100 Spy Court, Markham, Ontario, Canada L3R 5H6.
     
    Item 2.
    Identity and Background.
     
    This Schedule 13D is filed by the Reporting Persons. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of Lumira Capital II, L.P. and Lumira Capital II (International), L.P., and each of Lumira Capital II, L.P. and Lumira Capital II (International), L.P. is managed by Lumira Capital Investment Management Inc.  Each of Mr. van der Velden, Mr. Rovinski, Mr. Hetu, Mr. Brunk and Mr. Larcina are executive officers of Lumira Capital Investment Management Inc. and Mr. van der Velden, Mr. Rovinski, Mr. Hetu and Mr. Brunk are each directors of Lumira Capital Investment Management Inc.  The foregoing individuals collectively make investment decisions with respect to the securities held by each of  Lumira Capital II, L.P. and Lumira Capital II (International), L.P.  The principal address of the Reporting Persons is 141 Adelaide Street West, Suite 770, Toronto, Canada M5H 3L5.
     
    The Reporting Persons are venture capital investors that provide capital to early, clinical and revenue stage companies that are both privately held and publicly traded in the biotechnology, medical technologies, digital health and consumer healthcare sectors.
     
    During the last five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
     
    Item 3.
    Source and Amount of Funds or Other Consideration.
     
    This Amendment No. 3 does not amend the information previously provided in response to this Item 3.

    Item 4.
    Purpose of Transaction.
     
    This Amendment No. 3 does not amend the information previously provided in response to this Item 4.
     
    Item 5.
    Interest in Securities of the Issuer.
     
    (a)-(b)
     
    Number of Common Shares beneficially owned:

    Lumira Capital II, L.P.
    1,600,932 shares
    Lumira Capital II (International), L.P.
    148,038 shares
    Lumira Capital GP, L.P.
    1,748,970 shares
    Lumira GP Inc.
    1,748,970 shares
    Lumira GP Holdings Co.
    1,748,970 shares
    Lumira Capital Investment Management Inc.
    1,748,970 shares
    Peter van der Velden
    1,748,970 shares
    Benjamin Rovinski
    1,748,970 shares
    Daniel Hetu
    1,748,970 shares
    Gerald Brunk
    1,748,970 shares
    Vasco Larcina
    1,748,970 shares
     
    13

    Percent of class:

    Lumira Capital II, L.P.
    8.2%
    Lumira Capital II (International), L.P.
    0.8%
    Lumira Capital GP, L.P.
    9.0%
    Lumira GP Inc.
    9.0%
    Lumira GP Holdings Co.
    9.0%
    Lumira Capital Investment Management Inc.
    9.0%
    Peter van der Velden
    9.0%
    Benjamin Rovinski
    9.0%
    Daniel Hetu
    9.0%
    Gerald Brunk
    9.0%
    Vasco Larcina
    9.0%
     
    The percentage ownership was calculated based on a total of (i) 19,353,351 Common Shares issued and outstanding as of December 14, 2022, as reported in the Issuer’s Annual Report on Form 10-K filed with the Commission on December 16, 2022, and (ii) the number of Warrants issuable upon the exercise of the Warrants held by the Reporting Person (as disclosed in footnote 2 of each Reporting Person’s cover page).
     
    Number of shares as to which such person has:

    (i)
    Sole power to vote or to direct the vote:

    Lumira Capital II, L.P.
    0 shares
    Lumira Capital II (International), L.P.
    0 shares
    Lumira Capital GP, L.P.
    0 shares
    Lumira GP Inc.
    0 shares
    Lumira GP Holdings Co.
    0 shares
    Lumira Capital Investment Management Inc.
    0 shares
    Peter van der Velden
    0 shares
    Benjamin Rovinski
    0 shares
    Daniel Hetu
    0 shares
    Gerald Brunk
    0 shares
    Vasco Larcina
    0 shares

    (ii)
    Shared power to vote or to direct the vote:

    Lumira Capital II, L.P.
    1,600,932 shares
    Lumira Capital II (International), L.P.
    148,038 shares
    Lumira Capital GP, L.P.
    1,748,970 shares
    Lumira GP Inc.
    1,748,970 shares
    Lumira GP Holdings Co.
    1,748,970 shares
    Lumira Capital Investment Management Inc.
    1,748,970 shares
    Peter van der Velden
    1,748,970 shares
    Benjamin Rovinski
    1,748,970 shares
    Daniel Hetu
    1,748,970 shares
    Gerald Brunk
    1,748,970 shares
    Vasco Larcina
    1,748,970 shares

    (iii)
    Sole power to dispose or to direct the disposition of:

    Lumira Capital II, L.P.
    0 shares
    Lumira Capital II (International), L.P.
    0 shares
    Lumira Capital GP, L.P.
    0 shares
    Lumira GP Inc.
    0 shares
    Lumira GP Holdings Co.
    0 shares
    Lumira Capital Investment Management Inc.
    0 shares
    Peter van der Velden
    0 shares
    Benjamin Rovinski
    0 shares
    Daniel Hetu
    0 shares
    Gerald Brunk
    0 shares
    Vasco Larcina
    0 shares

    14

    (iv)
    Shared power to dispose or to direct the disposition of:

    Lumira Capital II, L.P.
    1,600,932 shares
    Lumira Capital II (International), L.P.
    148,038 shares
    Lumira Capital GP, L.P.
    1,748,970 shares
    Lumira GP Inc.
    1,748,970 shares
    Lumira GP Holdings Co.
    1,748,970 shares
    Lumira Capital Investment Management Inc.
    1,748,970 shares
    Peter van der Velden
    1,748,970 shares
    Benjamin Rovinski
    1,748,970 shares
    Daniel Hetu
    1,748,970 shares
    Gerald Brunk
    1,748,970 shares
    Vasco Larcina
    1,748,970 shares
     
    (c) The Reporting Persons have effected the following transactions with respect to the Common Shares of the Issuer during the past 60 days.
     
    On January 9, 2023, 132,845 Common Shares and 12,284 Common Shares were sold by LCII LP and LCII INT LP, respectively, at a price of US$2.6621 per Common Share
     
    On January 10, 2023, 139,450 Common Shares and 12,895 Common Shares were sold by LCII LP and LCII INT LP, respectively, at a price of US$2.6346 per Common Share.
     
    On January 11, 2023, 93,364 Common Shares and 8,633 Common Shares were sold by LCII LP and LCII INT LP, respectively, at a price of US$2.5544 per Common Share.
     
    On January 12, 2023, 27,379 Common Shares and 2,532 Common Shares were sold by LCII LP and LCII INT LP, respectively, at a price of US$2.5031 per Common Share.
     
    (d)-(e) Not applicable.

    Item 6.
    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
     
    This Amendment No. 3 does not amend the information previously provided in response to this Item 6.
     
    Item 7.
    Material to be Filed as Exhibits.
     
    This Amendment No. 3 does not amend the information previously provided in response to this Item 7.
     
    15

    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
    LUMIRA CAPITAL II, L.P.
    BY: LUMIRA CAPITAL GP, L.P.,
     
    ITS GENERAL PARTNER
     
    BY: LUMIRA GP INC.
     
    ITS GENERAL PARTNER
         
    Date:  January 13, 2023
    By:

    /s/ Vasco Larcina
     
    Name:

    Vasco Larcina
     
    Title:

    Chief Financial Officer

     
    LUMIRA CAPITAL II (INTERNATIONAL), L.P.
     
    BY: LUMIRA CAPITAL GP, L.P.,
     
    ITS GENERAL PARTNER
     
    BY: LUMIRA GP INC.
     
    ITS GENERAL PARTNER
         
    Date:  January 13, 2023
    By:

    /s/ Vasco Larcina
     
    Name:

    Vasco Larcina
     
    Title:

    Chief Financial Officer

     
    LUMIRA CAPITAL GP, L.P.
     
    BY: LUMIRA GP INC.,
     
    ITS GENERAL PARTNER
         
    Date:  January 13, 2023
    By:

    /s/ Vasco Larcina
     
    Name:

    Vasco Larcina
     
    Title:

    Chief Financial Officer

     
    LUMIRA GP INC.
         
    Date:  January 13, 2023
    By:

    /s/ Vasco Larcina
     
    Name:

    Vasco Larcina
     
    Title:

    Chief Financial Officer

     
    LUMIRA GP HOLDINGS CO.
         
    Date:  January 13, 2023
    By:

    /s/ Vasco Larcina
     
    Name:

    Vasco Larcina
     
    Title:

    Chief Financial Officer

     
    LUMIRA CAPITAL INVESTMENT MANAGEMENT INC.
         
    Date:  January 13, 2023
    By:

    /s/ Vasco Larcina
     
    Name:

    Vasco Larcina
     
    Title:

    Chief Financial Officer

    Date:  January 13, 2023
    By:
     
    /s/ Peter van der Velden

    Date:  January 13, 2023
    By:
     
    /s/ Benjamin Rovinski

    Date:  January 13, 2023
    By:
     
    /s/ Daniel Hetu

    Date:  January 13, 2023
    By:
     
    /s/ Gerald Brunk

    Date:  January 13, 2023
    By:
     
    /s/ Vasco Larcina


    16

    Get the next $EDSA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EDSA

    DatePrice TargetRatingAnalyst
    12/20/2021$16.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EDSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Edesa Biotech Inc.

      SC 13D/A - Edesa Biotech, Inc. (0001540159) (Subject)

      11/1/24 8:50:52 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Edesa Biotech Inc.

      SC 13G - Edesa Biotech, Inc. (0001540159) (Subject)

      6/3/24 4:10:38 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Edesa Biotech Inc. (Amendment)

      SC 13G/A - Edesa Biotech, Inc. (0001540159) (Subject)

      1/29/24 4:29:02 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Nijhawan Pardeep was granted 6,392 shares, increasing direct ownership by 4% to 178,923 units (SEC Form 4)

      4 - Edesa Biotech, Inc. (0001540159) (Issuer)

      5/6/25 5:28:21 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Weiler Peter J.

      3 - Edesa Biotech, Inc. (0001540159) (Issuer)

      5/2/25 5:00:21 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Nijhawan Pardeep was granted 5,784 shares, increasing direct ownership by 3% to 172,531 units (SEC Form 4)

      4 - Edesa Biotech, Inc. (0001540159) (Issuer)

      4/3/25 5:25:30 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

      TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for May 5-6 2025 in Toronto, Ontario. Edesa management is scheduled to present on Monday, May 5 at 4:00pm ET. To meet with Edesa during the conference, please utilize the conference's online portal or contact the company directly at [email protected]. About Edesa Biotech Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company develop

      4/28/25 4:30:06 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Announces Chief Financial Officer Transition

      TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage ph

      4/4/25 4:15:46 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

      TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2024 and provided an update on its business. During the quarter, the company advanced its main asset, EB06, an anti-CXCL10 monoclonal antibody candidate being developed for the effective and durable treatment of vitiligo. Preparation for the manufacturing campaign is underway, with data anticipated to be submitted to regulators at the U.S. Food and Drug Administration (FDA) during the middle of 2025. The company in

      2/14/25 4:15:00 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Nijhawan Pardeep bought $20,000 worth of shares (5,000 units at $4.00) (SEC Form 4)

      4 - Edesa Biotech, Inc. (0001540159) (Issuer)

      3/25/24 7:00:59 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    Leadership Updates

    Live Leadership Updates

    See more
    • Edesa Biotech Announces Chief Financial Officer Transition

      TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage ph

      4/4/25 4:15:46 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

      TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of directors has appointed Stephen Lemieux, CPA to the role of Chief Financial Officer, effective July 15, 2023. He is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of experience in financial planning and analysis, licensing and mergers & acquisitions."Stephen joins Edesa at an exciting time as we build on our regulatory and clinical achievements and set our sights on additional growth opportunities. He shares our disciplined, manage-like-owner

      6/27/23 8:15:00 AM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Appoints Strategy Expert to Board of Directors

      TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of Jennifer M. Chao to the company's Board of Directors."Ms. Chao's appointment to our Board comes at an exciting time as we prepare for the most meaningful milestones yet in our clinical programs. Her extensive experience in the life science sector and capital markets will be a valuable resource to Edesa and its shareholders," said Par Nijhawan, MD, Chief Executive Officer of Edesa.Ms. Chao has more than 25 years of experience in the biotech and life sciences industries focused primarily

      3/29/22 9:00:00 AM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Edesa Biotech with a new price target

      HC Wainwright & Co. initiated coverage of Edesa Biotech with a rating of Buy and set a new price target of $16.00

      12/20/21 6:08:21 AM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Edesa Biotech Inc.

      DEFA14A - Edesa Biotech, Inc. (0001540159) (Filer)

      4/4/25 4:23:38 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Edesa Biotech Inc.

      DEF 14A - Edesa Biotech, Inc. (0001540159) (Filer)

      4/4/25 4:22:10 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Edesa Biotech, Inc. (0001540159) (Filer)

      4/4/25 4:20:14 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care